COMPARE · Data as of August 21, 2026
AZN vs HIMS
Verdict: Side-by-side breakdown using the Bull Rankings model. AZN scored 74.5, HIMS scored 39.3 — AZN leads.
Compare another set
Different reporting periods. HIMS's fundamentals are as of June 2026, but AZN's are as of December 2025 — a 6-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
AZN
AstraZeneca PLC
74.5
$165.98 · $257.4B
fundamentals as of
Score gap
35.2
AZN leads
HIMS
Hims & Hers Health, Inc.
39.3
$31.13 · $7.3B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthHIMS+28.0%
- Strongest balance sheetAZN0.64
- Highest qualityAZN78 / 100
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
AZN
stronger →← stronger
HIMS
78
Qualityreturns · margins · balance sheet
23
78
Growthrevenue & earnings expansion
93
68
Valuevaluation vs sector peers
29
AZN is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
AZN
HIMS
$11.8bA-
FCF
$62mC-
+8.6%B
Rev
+28.0%A-
0.64C+
D/E
4.77D
24.9xB
P/E
—
1.42B
PEG
2.15C
—
P/S
2.8xB+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
AZN
HIMS
19% above
Price vs fair valuelower is cheaper
777% above
~13%/yr
Growth the price implies10-yr FCF · lower = less priced in
>60%/yr
-26%
1-yr DCF upside
-91%
-16%
5-yr DCF upside
-89%
+1%
10-yr DCF upside
-84%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
AZN
Why this score
- Raising its dividend
HIMS
Why this score
- Diluting shareholders
The companies
AZNAstraZeneca PLC
Why now
Drug Manufacturers - General · market cap $257.4b. Down 22% from 52-week high of $212.71 — deep drawdown territory. 10 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $213.99 (implying +29% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 21% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HIMSHims & Hers Health, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $7.3b. Down 52% from 52-week high of $65.30 — deep drawdown territory. Revenue growing +28% — in hypergrowth territory. 13 sell-side analysts rate this a Hold with a mean 1-yr target of $30.85 (implying -1% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 4.77 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Currently unprofitable (margin -5.5%) — path to GAAP profitability is the core thesis risk. Down 52% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where AZN and HIMS diverge
On the headline score the gap is 35.2 points in favor of AZN. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityAZN 78.2 · HIMS 22.7AZN +55.5
- ValueAZN 67.5 · HIMS 28.8AZN +38.7
- GrowthAZN 78.5 · HIMS 92.8HIMS +14.3
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.